JUPITER, Fla., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in the following upcoming investor conferences: Citi 20th Annual BioPharma Conference (Boston): Management will participate in a fireside chat on September 3, 2025 at 11:15 a.m. ET. H.C. Wainwright 27th Annual Global Investment Conference (New York): Management will present on September 9, 2025 a ...

REIT also announces monthly distributions for Q4 2025MONTRÉAL, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Canadian Net Real Estate Investment Trust (“Canadian Net” or the “REIT”) (TSX-V: NET.UN) today reported its results for the quarter ended June 30th, 2025 (“Q2 2025”) and distributions for October, November and December 2025. “We are pleased with our second quarter results, highlighted by an 8% year-to-date increase in FFO per unit1,” said Kevin Henley, President and CEO. “This quarter reflects the full impact of ...

Texas Attorney General Ken Paxton secured a $9.5 million settlement with Booking Holdings to resolve a lawsuit in which Paxton alleged that the online travel agency engaged in deceptive “junk fee” practices.By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions .Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS ...

Dividends, buybacks, and many are approaching net-cash positions. Wait, this must be a mistake; we’re talking about gold miners here. Traditionally, this would have been the case, but over the past couple of years, gold miners have entered a new golden age.Mountain Valley Value Investments specializes in identifying undervalued companies with strong growth potential across various sectors. Focused on long-term value and buying at the right price, we leverage deep industry insights and rigorous analysis to u ...

Group 1 - Samuel Smith has extensive experience in dividend stock research and investment, having served as lead analyst and Vice President at several firms [1] - He is a Professional Engineer and Project Management Professional with degrees in Civil Engineering & Mathematics and a Master's in Engineering focused on applied mathematics and machine learning [1] - Samuel leads the High Yield Investor investing group, collaborating with Jussi Askola and Paul R. Drake to balance safety, growth, yield, and value [2] Group 2 - High Yield Investor provides real-money core, retirement, and international portfolios, along with regular trade alerts and educational content [2] - The service includes an active chat room for like-minded investors to share insights and strategies [2]

Core Insights - The beverage offerings at top restaurant chains have increased by over 9% in the past year, driven by younger consumers seeking customized cold drinks [4] - The primary reason for beverage purchases has shifted, with 22% of consumers now buying drinks for a "pick-me-up," up from 20% in 2023, indicating a trend towards beverage-specific occasions [5][6] - Major players like McDonald's and Starbucks are focusing on innovative beverage options to drive sales, with McDonald's reporting a 2.5% same-store sales growth in its second fiscal quarter [6][14] Industry Trends - The demand for cold beverages, particularly specialty coffees and energy drinks, has surged, while hot beverages are declining [4] - Technomic forecasts a 1% growth in beverage volume through 2029, but this outlook may be revised lower due to increased price sensitivity among consumers [7][8] - Gen Z consumers are particularly influential in the beverage market, favoring customized and sugary drinks, as seen with Dunkin's Refreshers platform, which saw unit sales increase by over 30% year-on-year [9][10] Company Strategies - Dunkin' plans to expand its beverage lineup with new offerings aimed at Gen Z, including a Cereal N' Milk Latte and new flavors of its Refreshers [10][13] - McDonald's is set to launch new drinks, including a "Creamy Vanilla Cold Brew" and "Toasted Vanilla Frappe," in a test across 500 restaurants, targeting Gen Z consumers [13][14] - Starbucks is innovating with new menu items like protein cold foam, which adds 15 grams of protein to beverages, aiming to enhance customer satisfaction among younger demographics [17][18] Competitive Landscape - Dutch Bros has experienced strong growth, with same-store sales increasing over 6% in the most recent quarter, attributed to unique offerings and innovative toppings [19][20] - The beverage segment is seen as more profitable than food, prompting companies to focus on high-margin beverage products [15]

Core Viewpoint - Tevogen Bio Holdings Inc. has secured a financing agreement of up to $50 million, which includes a $36 million line of credit and a potential $14 million private placement, following the elimination of $94.9 million in liabilities, aimed at supporting its R&D efforts and expanding its intellectual property portfolio [1][2][3]. Financing Details - The financing structure consists of a $36 million line of credit, allowing access to $1 million per month at an interest rate of the lower of the daily SOFR plus 2.0% or 7.0%, with a maturity of four years after each draw [3]. - The $14 million private placement can be executed at the counterparty's option once the share price reaches $10, priced at a 30% discount to that price [4]. Business Model and R&D Focus - Tevogen's innovative business model is designed to enhance research and development, particularly for its initial product, TVGN 489, derived from the ExacTcell™ technology platform [2]. - The company currently holds three granted US patents and has nine pending US patent applications, along with twelve ex-US patent applications, indicating a strong intellectual property position [2][6]. Leadership and Vision - Tevogen is led by a team of experienced industry leaders and scientists, emphasizing the importance of accessible personalized therapeutics as the next frontier in medicine [7]. - The company aims to provide affordable and accessible personalized T cell therapies to address significant unmet needs in large patient populations [5][6].

About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Viewpoint - Thermo Fisher Scientific Inc. is positioned as a potential leader in the biopharma sector, with analysts optimistic about a turnaround driven by strategic acquisitions and growth potential despite recent stock performance lagging [1][6]. Financial Performance - Thermo Fisher reported second-quarter 2025 adjusted earnings of $5.36 per share, exceeding the expected $5.23, with quarterly sales of $10.86 billion, a 3% year-over-year increase, surpassing the analyst consensus estimate of $10.68 billion [4]. - The company has delivered a 290% return since 2015, outperforming the S&P 500's 213% return, although shares have declined 27% since the end of 2021 while the S&P gained over 30% [2]. Strategic Acquisitions and Growth - Since 2017, Thermo Fisher has made significant acquisitions and organic investments, which now account for over 60% of laboratory products and biopharma services revenue, and approximately one-third of total company sales [3]. - The company plans to invest an additional $2 billion in the U.S. over the next four years to address tariff challenges [5]. Future Outlook - Analysts project an EPS of $27.17 in 2027, with expectations that resolution of current challenges and appreciation for Thermo's pharma partnership strategy will improve its valuation multiple to around 22 times, suggesting a share price of approximately $598 by the end of 2026, indicating a 22% upside from current levels [6]. - The company is viewed as a key partner in the biopharma industry, with a strong balance sheet and M&A track record positioning it for further expansion in high-growth areas like bioproduction [7][8]. Market Position - Thermo Fisher is considered the partner of choice in the biopharma sector, with expectations for continued M&A activity to enhance market share and improve returns on invested capital over time [8].

Core Viewpoint - Inflationary concerns are impacting the stock market, leading to significant sell-offs in SoundHound AI stock, which is down 10.5% amid broader market declines [1][2][5] Group 1: Market Context - SoundHound AI stock is experiencing a valuation decline due to bearish pressures in the market, with the S&P 500 and Nasdaq Composite also showing declines of 0.8% and 1.6% respectively [1] - Home Depot's announcement of price increases due to tariffs raises concerns about inflation affecting the broader U.S. economy, which could impact valuations across the stock market [2][4] Group 2: Inflation and Economic Indicators - Home Depot's pricing strategy is seen as a macroeconomic indicator, suggesting that inflation at the wholesale level may affect consumer prices, creating a challenging environment for growth-dependent tech stocks [4][5] - The Producer Price Index (PPI) report indicated inflation levels above forecasts, intensifying fears of rising consumer-level inflation that could slow down the Federal Reserve's interest rate reduction plans [5][6] Group 3: Company Performance and Outlook - Despite current market pressures, SoundHound AI has shown impressive sales growth momentum and has significant long-term expansion potential, making it a more attractive investment compared to other speculative AI stocks [7] - The company's valuation, trading at approximately 30 times expected earnings without posting profits, is highly sensitive to macroeconomic developments, indicating potential for further sell-offs if inflationary pressures persist [5][6]